ReviewJournal of intensive medicine2023
Hemodynamic monitoring in cardiogenic shock.
Review in Journal of intensive medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.
- The quantitative haemodynamic effect of levosimendan, dobutamine, and milrinone in heart failure patients: a meta-analysis.ESC heart failure · 2026Pooled it
- ESICM guidelines on circulatory shock and hemodynamic monitoring 2025.Intensive care medicine · 2025Guideline
- Disparities in the management of cardiogenic shock complicating acute myocardial infarction: a questionnaire survey in Beijing.BMC cardiovascular disorders · 2026Article
- The Role of PoCUS in the Diagnosis and Early Monitoring of Cardiogenic Shock in the Emergency Department: A Narrative Review.Reviews in cardiovascular medicine · 2026Review
- Timing of veno-arterial extracorporeal membrane oxygenation in cardiogenic shock: A systematic review and meta-analysis.Journal of intensive medicine · 2026Article
- Feasibility of a noninvasive photoplethysmography-based wearable chest patch for cardiac output assessment during exercise compared with thermodilution right heart catheterization.Scientific reports · 2026Article
- Nurses' competence in hemodynamic monitoring and Its impact on clinical decision-making in cardiac ICUs.Frontiers in cardiovascular medicine · 2026Article
- Article
- PiCCO hemodynamic parameters in cardiogenic shock: prediction of LVEF, NT-proBNP and MACE based on XGBoost machine learning model.Frontiers in medicine · 2025Article
- PiCCO or Cardiac Ultrasound? Which Is Better for Hemodynamic Monitoring in ICU?Medicina (Kaunas, Lithuania) · 2024Review
- Perioperative Complications in Infective Endocarditis.Journal of clinical medicine · 2023Review
- From Acute heart failure to cardiogenic shock patients requiring admission in ICU.Journal of intensive medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiogenic shock (CS) is a life-threatening condition characterized by acute end-organ hypoperfusion due to inadequate cardiac output that can result in multiorgan failure, which may lead to death. The diminished cardiac output in CS leads to systemic hypoperfusion and maladaptive cycles of ischemia, inflammation, vasoconstriction, and volume overload. Obviously, the optimal management of CS needs to be readjusted in view of the predominant dysfunction, which may be guided by hemodynamic monitoring. Hemodynamic monitoring enables (1) characterization of the type of cardiac dysfunction and the degree of its severity, (2) very early detection of associated vasoplegia, (3) detection and monitoring of organ dysfunction and tissue oxygenation, and (4) guidance of the introduction and optimization of inotropes and vasopressors as well as the timing of mechanical support. It is now well documented that early recognition, classification, and precise phenotyping via early hemodynamic monitoring (e.g., echocardiography, invasive arterial pressure, and the evaluation of organ dysfunction and parameters derived from central venous catheterization) improve patient outcomes. In more severe disease, advanced hemodynamic monitoring with pulmonary artery catheterization and the use of transpulmonary thermodilution devices is useful to facilitate the right timing of the indication, weaning from mechanical cardiac support, and guidance on inotropic treatments, thus helping to reduce mortality. In this review, we detail the different parameters relevant to each monitoring approach and the way they can be used to support optimal management of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.